Bone mineral density in patients with alopecia areata treated with long-term intralesional corticosteroids

Journal of Drugs in Dermatology

Volumn 12, Issue 2, 2013, Pages

  Samrao, Aman ^a   Fu, Jennifer M ^a,b   Harris, Steven T ^b   Price, Vera H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Private Practice   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PREDNISONE; TRIAMCINOLONE ACETONIDE; VITAMIN D;

ADULT; AGED; ALOPECIA AREATA; ARTICLE; BODY MASS; BONE DENSITY; CLINICAL ARTICLE; CROSS-SECTIONAL STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; FAMILY HISTORY; FEMALE; FOLLOW UP; HUMAN; LUMBAR SPINE; MALE; OSTEOPENIA; OSTEOPOROSIS; PATCHY ALOPECIA AREATA; POSTMENOPAUSE; RESISTANCE TRAINING; RETROSPECTIVE STUDY; RISK FACTOR; SMOKING; STRESS FRACTURE; TREATMENT DURATION;

ABSORPTIOMETRY, PHOTON; ADRENAL CORTEX HORMONES; ADULT; AGE FACTORS; AGED; ALOPECIA AREATA; ANTI-INFLAMMATORY AGENTS; BONE DENSITY; BONE DISEASES, METABOLIC; CALCIUM; DIETARY SUPPLEMENTS; EYEBROWS; FEMALE; FRACTURES, STRESS; HUMANS; INJECTIONS, INTRALESIONAL; MALE; MIDDLE AGED; POSTMENOPAUSE; PREDNISONE; RISK FACTORS; SCALP; SEDENTARY LIFESTYLE; SMOKING; SPINE; TRIAMCINOLONE; VITAMIN D; VITAMINS; YOUNG ADULT;

EID: 84873366847     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Safavi K. Prevalence of alopecia areata in the First National Health and Nutrition Examination Survey. Arch Dermatol. 1992;128(5):702.
2. Safavi KH, Muller SA, Suman VJ, Moshell AN, Melton LJ 3rd. Incidence of alopecia areata in Olmsted County, Minnesota, 1975 through 1989. Mayo Clin Proc. 1995;70(7):628-633.
3. Gilhar A, Paus R, Kalish RS. Lymphocytes, neuropeptides, and genes involved in alopecia areata. J Clin Invest. 2007;117(8):2019-2027.
4. Price VH, Colombe BW. Heritable factors distinguish two types of alopecia areata. Dermatol Clin. 1996;14(4):679-689
5. Price VH. Therapy of alopecia areata: on the cusp and in the future. J Investig Dermatol Symp Proc. 2003;8(2):207-211.
6. Walsh LJ, Lewis SA, Wong CA, et al. The impact of oral corticosteroid use on bone mineral density and vertebral fracture. Am J Respir Crit Care Med. 2002;166(5):691-695.
7. McDonough AK, Curtis JR, Saag KG. The epidemiology of glucocorticoidassociated adverse events. Curr Opin Rheumatol. 2008;20(2):131-137.
8. Allport J. Incidence and prevalence of medication-induced osteoporosis: evidence-based review. Curr Opin Rheumatol. 2008;20(4):435-441.
9. Vestergaard P, Rejnmark L, Mosekilde L.Fracture risk associated with different types of oral corticosteroids and effect of termination of corticosteroids on the risk of fractures. Calcif Tissue Int. 2008;82(4):249-257.
10. Tattersfield AE, Harrison TW, Hubbard RB, Mortimer K. Safety of inhaled corticosteroids. Proc Am Thorac Soc. 2004;1(3):171-175.
11. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359(9321):1929-1936.
12. Canalis E. Mechanisms of glucocorticoid action in bone. Curr Osteoporos Rep. 2005;3(3):98-102.
13. Lane NE. An update on glucocorticoid-induced osteoporosis. Rheum Dis Clin North Am. 2001;27(1):235-253.
14. Vermaat H, Kirtschig G. Prevention and treatment of glucocorticoid- induced osteoporosis in daily dermatologic practice. Int J Dermatol. 2008;47(7):737-742.